Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
VERU
VERU
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VERU News
Veru Initiates Phase 2b Clinical Trial for Enobosarm in Obesity Treatment
1d ago
Newsfilter
Veru Inc. to Present at Oppenheimer Healthcare Conference
Feb 19 2026
Newsfilter
Veru Inc. Q1 2026 Earnings Call Insights
Feb 11 2026
seekingalpha
Veru Reports Q1 2025 Earnings with Significant Cash Increase
Feb 11 2026
seekingalpha
Veru Initiates Phase 2b Clinical Trial for Obesity Drug Enobosarm
Feb 11 2026
Newsfilter
Veru Scheduled to Announce Q1 Earnings on February 11
Feb 10 2026
seekingalpha
Veru details 72-week Phase IIb PLATEAU study aimed at obesity plateau group in accordance with FDA recommendations.
Dec 17 2025
SeekingAlpha
Key Stocks Reporting Earnings This Week: Micron, FuelCell, Carnival, and Others
Dec 15 2025
Benzinga
Verusen Promotes Stuart Lynch to Director of Customer Success, Enhancing Supply Chain Optimization
Dec 05 2025
Globenewswire
Veru to Showcase Two Abstracts at ObesityWeek 2025
Oct 31 2025
Newsfilter
Eli Lilly Halts Bimagrumab Obesity Trial Just Weeks After Initiation
Sep 25 2025
Benzinga
Veru outlines Phase III plans for enobosarm and signals upcoming FDA clarity on lean mass preservation in obesity treatment
Aug 12 2025
SeekingAlpha
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
Aug 12 2025
Newsfilter
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
Aug 11 2025
Newsfilter
Upcoming Stock Splits This Week (August 11 to August 15) – Stay Invested
Aug 10 2025
TipRanks
Why Veru Inc. Is Rising In Pre-market?
Jun 24 2025
NASDAQ.COM
Show More News
